SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is trending as investors react to the company's recent leadership transition, the appointment of former Pfizer CMO Dr. Freda Lewis-Hall to its board, and anticipation surrounding upcoming Phase 2 data for its GAD program. The community remains polarized, with some highlighting the company's robust IP portfolio and institutional accumulation, while others express concerns over the stock's historical volatility and ongoing cash burn.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is facing downward pressure following significant insider selling by the CEO, sparking community frustration regarding management's long-term strategy and a desire for an acquisition. Despite these concerns, investors remain focused on the potential of the Casgevy commercial rollout and upcoming clinical data readouts across the firm's gene-editing pipeline.

Beamable Network is a decentralized compute infrastructure designed to power real games and digital experiences. Built by the team behind Beamable Inc.—a backend platform already serving over 95 live games—the network transforms compute into an open, tokenized marketplace. By combining distributed node operators, verifiable workloads, and blockchain incentives, Beamable Network provides scalable, cost-efficient infrastructure for any compute applications without dependence on centralized cloud providers.

Beamable Network Token

Beamable Network Token is experiencing heightened community interest driven by rapid price volatility and significant order book activity. Traders are actively tracking potential breakout patterns while debating the sustainability of the current momentum amid broader market speculation.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors weigh an upcoming Phase 3 readout for its hereditary angioedema therapy alongside significant volatility driven by high short interest and speculative sentiment. The community is actively debating the stock's potential as a binary event, with many focused on the interplay between clinical trial expectations, short-squeeze potential, and broader biotech sector momentum.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is trending as investors monitor significant short interest and volatility following recent ASH presentations and potential M&A speculation. The community is actively discussing the company's transition into a profitable commercial entity while awaiting further catalysts like potential pipeline updates or partnership news.

Chip

Chip is experiencing significant volatility and social media attention following its debut on major trading platforms, sparking a fierce debate among traders over whether it is a legitimate AI infrastructure utility or a speculative pump-and-dump scheme. The community is actively tracking support levels and debating the long-term potential of the token as it navigates price discovery and high trading volumes.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgen is seeing heavy market engagement as investors weigh strong Q2 earnings, which featured double-digit volume growth in key assets like Repatha and Evenity, against concerns over pricing pressures and patent cliffs. The community is actively discussing Amgens competitive positioning in the high-stakes obesity pipeline alongside speculation regarding future M&A potential and the company's long-term manufacturing expansion strategy.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors react to a significant management overhaul that includes the removal of CEO Peter Greenleaf and a total leadership restructuring led by the company's largest shareholder, Kevin Tang. The community is actively discussing the potential for an accelerated buyout and a strategic pivot to maximize shareholder value following these executive departures.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney is facing intense scrutiny as a leadership transition to incoming CEO Josh D'Amaro highlights ongoing concerns regarding operational efficiency, content performance, and market stagnation. The community is actively debating the stock's long-term viability, weighing the company's streaming profitability and park demand against frustrations over persistent share price underperformance and polarizing creative strategies.

The Last Play is Crypto’s 401k.  RETIRE is more than a coin; it’s The Last Play. We are a community dedicated to breaking free from the grind and building true generational wealth. With RETIRE, our mission is simple yet profound: to provide a pathway to retire yourself and secure financial freedom for your bloodline. While others chase hype and trends, we’re focused on creating a legacy that lasts beyond the typical cycle. RETIRE is about making the one move that matters, with a vision for long-term value, freedom, and impact. This isn’t just a meme —it’s a purpose-driven commitment to building a legacy.

The Last Play

$RETIRE is capturing significant community attention as a grassroots movement aimed at replacing traditional 401(k) systems, with supporters actively participating in weekly dollar-cost averaging to fuel long-term growth. Investors are currently focused on its potential for a major breakout, viewing the token as a life-changing financial alternative that stands in defiance of established, centralized retirement models.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


Onbetmexcom

Onbet mexcom